Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Stamford, ConnecticutAges 18 years+ - NCT04489342Recruiting
Tests sensor-based movement assessment in axial spondyloarthritis patients
This trial studies an advanced “sensor-based” way to assess how your spine and hips move in people with axial spondyloarthritis. It may help researchers better measure function and choose/monitor treatment, especially for those considered for biologic therapy.
Londonderry, N.IrelandAges 18–80 - NCT04529044RecruitingPhase 2
177Lu-DOTATATE for advanced breast cancer with targeted receptors
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
Portland, OregonAges 18–100 - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Los Angeles, CaliforniaAges 18 years+ - NCT04535713RecruitingPhase 2
Testing chemotherapy plus immunotherapy for advanced sarcoma
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
Santa Monica, CaliforniaAges 18 years+ - NCT04577014RecruitingPhase 1/Phase 2
Retifanlimab plus chemotherapy for advanced soft tissue sarcoma
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
New York, New YorkAges 18 years+ - NCT04698252RecruitingPhase 2
Local treatment for ER/PR-positive limited spread breast cancer
This Phase 2 study tests whether treating a small number of metastatic spots with a local approach (like targeted radiation, surgery, or ablation) can help people with ER/PR-positive breast cancer. It aims to help when the cancer has spread only to a few areas and has not significantly worsened after initial whole-body treatment.
São Paulo, São PauloAges 18 years+ - NCT04722978RecruitingPhase 3
Chemo plus moxifloxacin for metastatic triple-negative breast cancer
This trial tests whether adding moxifloxacin (an antibiotic) to standard chemotherapy helps people with metastatic triple-negative breast cancer live longer or respond better. You may qualify if your cancer has the right lab markers and you haven’t had treatment for metastatic disease yet.
Guangzhou, GuangdongAges 18–70 - NCT04768322Recruiting
LVAD versus standard heart failure medicines in advanced patients
This trial compares an LVAD device (a pump placed in the chest) plus medicines versus medicines alone for people with advanced, end-stage heart failure. It aims to see which approach works better to help patients live and stay out of the hospital.
BesançonAges 18 years+ - NCT04777084RecruitingPhase 2
Lenvatinib plus PD-1 antibody for advanced lung cancer
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
Changsha, HunanAges 18–75 - NCT04817956RecruitingPhase 2
Precision-medicine treatment for advanced cancer in Norway
This Phase 2 trial tries to match people with advanced cancer to targeted treatments based on their tumor’s genetic results. It may help if standard cancer treatments are no longer working or aren’t available, and if a “target” in the tumor suggests a therapy that could work.
ÅlesundAges 16 years+ - NCT04823403RecruitingPhase 1
Targeted liver delivery of immunotherapy for advanced liver cancer
This early-phase study tests how well giving ipilimumab directly into the liver (via an artery) and nivolumab through a vein works for advanced hepatocellular carcinoma (liver cancer). It is for people whose cancer cannot be removed with surgery or treated with a transplant, especially after standard treatment failed or wasn’t tolerated.
VillejuifAges 18 years+ - NCT04868604RecruitingPhase 1/Phase 2
Copper PSMA scan and treatment for prostate cancer in men on low testosterone
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
Stanford, CaliforniaAges 18 years+ - NCT04927416RecruitingPhase 2
Ga-DOTATATE PET/CT scan in metastatic thyroid cancer
This study tests whether a specific special scan (68-Gallium DOTATATE PET/CT) can help doctors better see where thyroid cancer has spread. It focuses on certain types of thyroid cancer and compares how well the scan images metastases.
Bethesda, MarylandAges 18–98 - NCT05874414RecruitingPhase 1/Phase 2
Combination therapy for advanced KRAS-mutated bile duct cancer
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT04944030Recruiting
Study collects health data for metastatic lung cancer patients
This study collects medical information and test results from people with lung cancer that has spread (or cannot be cured with local treatment). It does not test a new drug; it helps researchers better understand patients’ health and care needs over time.
AngersAges 18 years+ - NCT04954781RecruitingPhase 2
Chemo plus immunotherapy for advanced bile duct liver cancer
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT04975152RecruitingPhase 1
Cemiplimab before surgery for Merkel cell and skin cancers
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
Tampa, FloridaAges 18 years+ - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT04995003RecruitingPhase 1
HER2 CAR T plus pembrolizumab for advanced HER2 sarcoma
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
Houston, TexasAges 1–25 - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05037331Recruiting
Osimertinib for advanced EGFR-mutated lung cancer
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
SingaporeAges 21–99 - NCT05065957RecruitingPhase 2/Phase 3
Study of two oral chemo medicines for advanced bile duct cancer
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
Kaohsiung CityAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.